Evidence map›Paper›PMID 39964590›Full record

ArticleBreast cancer (Tokyo, Japan)2025

A novel formula to improve the accuracy and prognostic ability of determining the survival time after recurrent breast cancer.

Reiki Nishimura, Yasuaki Sagara, Reiko Mitsueda, Tetsuhiko Taira, Toshiko Miyaki, Shuichi Kanemitsu, Megumi Teraoka, Junko Kawano, Naomi Gondo, Yoshitaka Fujiki and 6 more

Abstract read
PubMed Publisher
In one paragraph

Article in Breast cancer (Tokyo, Japan), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Reiki NishimuraDepartment of Breast and Thyroid Surgical Oncology, Sagara Hospital, Social Medical Corporation Hakuaikai, Kagoshima City, Kagoshima, 892-0833, Japan. nishirei@ymail.ne.jp.ORCID http://orcid.org/0000-0003-0645-7880
Yasuaki SagaraDepartment of Breast and Thyroid Surgical Oncology, Sagara Hospital, Social Medical Corporation Hakuaikai, Kagoshima City, Kagoshima, 892-0833, Japan.
Reiko MitsuedaDepartment of Breast and Thyroid Surgical Oncology, Sagara Hospital, Social Medical Corporation Hakuaikai, Kagoshima City, Kagoshima, 892-0833, Japan.
Tetsuhiko TairaClinical Oncology, Sagara Hospital, Social Medical Corporation Hakuaikai, Kagoshima City, Japan.
Toshiko MiyakiClinical Oncology, Sagara Hospital, Social Medical Corporation Hakuaikai, Kagoshima City, Japan.
Shuichi KanemitsuDepartment of Breast and Thyroid Surgical Oncology, Sagara Hospital, Social Medical Corporation Hakuaikai, Kagoshima City, Kagoshima, 892-0833, Japan.
Megumi TeraokaDepartment of Breast and Thyroid Surgical Oncology, Sagara Hospital, Social Medical Corporation Hakuaikai, Kagoshima City, Kagoshima, 892-0833, Japan.
Junko KawanoDepartment of Breast and Thyroid Surgical Oncology, Sagara Hospital, Social Medical Corporation Hakuaikai, Kagoshima City, Kagoshima, 892-0833, Japan.
Naomi GondoDepartment of Breast and Thyroid Surgical Oncology, Sagara Hospital, Social Medical Corporation Hakuaikai, Kagoshima City, Kagoshima, 892-0833, Japan.
Yoshitaka FujikiDepartment of Breast and Thyroid Surgical Oncology, Sagara Hospital, Social Medical Corporation Hakuaikai, Kagoshima City, Kagoshima, 892-0833, Japan.
Ryutaro HigashiRadiology, Sagara Hospital, Social Medical Corporation Hakuaikai, Kagoshima City, Japan.
Akiko SembaRadiology, Sagara Hospital, Social Medical Corporation Hakuaikai, Kagoshima City, Japan.
Yasuyo OhiPathology, Sagara Hospital, Social Medical Corporation Hakuaikai, Kagoshima City, Japan.
Yoshiaki RaiDepartment of Breast and Thyroid Surgical Oncology, Sagara Hospital, Social Medical Corporation Hakuaikai, Kagoshima City, Kagoshima, 892-0833, Japan.
Yoshiaki SagaraDepartment of Breast and Thyroid Surgical Oncology, Sagara Hospital, Social Medical Corporation Hakuaikai, Kagoshima City, Kagoshima, 892-0833, Japan.
Shinji OhnoDepartment of Breast and Thyroid Surgical Oncology, Sagara Hospital, Social Medical Corporation Hakuaikai, Kagoshima City, Kagoshima, 892-0833, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRecurrent breast cancer (BC) has poor prognosis. To ascertain the survival time after recurrence (STR) is necessary for improving QOL and for selecting appropriate treatment. An investigation was conducted to determine whether certain biomarkers would improve prognosis and whether the disease-free interval (DFI) and biomarkers can predict STR.

methodsCases (n = 1,254) with recurrent BC from January 2000 to December 2023 were enrolled in this study. The cases were divided into the 2000-2005 group (n = 182), 2006-2011 group (n = 331), 2012-2017 group (n = 369), and 2018-2023 group (n = 366). A simple linear regression model was used to identify the relationship between STR and DFI.

resultsSurvival rates after recurrence significantly increased in cases after 2012. No improvement was observed in cases with a HER2-0 status and a Ki-67 index value < 15%. A multivariate analysis revealed that the Ki-67 index value was a significant factor in the 2000-2005 group. The ER and HER2 status were significant after 2012. The most significant correlation was found between DFI and STR in deceased patients with a Ki-67 index value > 30%, followed by HER2-low, tumor size ≤ 2 cm and ER < 1%. The following formula was developed to predict STR;

Indexed as

Breast NeoplasmsNeoplasm Recurrence, LocalAdultAgedBiomarkers, TumorDisease-Free SurvivalErb-b2 Receptor Tyrosine KinasesFemaleHumansKi-67 AntigenMiddle AgedPrognosisReceptors, EstrogenRetrospective StudiesSurvival RateBiomarkers, TumorERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesKi-67 AntigenReceptors, EstrogenBreast cancerDisease-free intervalKi-67RecurrenceSurvival after recurrence

Identifiers

PMID39964590

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.